P97 fusion proteins
AssigneeBioasis Technologies, Inc.
InventorsTimothy Z. Vitalis, Reinhard Gabathuler
Life of this patent
Estimating the term…
Abstract
Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
Claims12
A fusion protein, comprising a trastuzumab heavy chain sequence comprising the amino acid sequence of SEQ ID NO:29 fused to the N-terminus or the C-terminus of a peptide fragment comprising an amino acid sequence at least 80% identical to DSSHAFTLDELR (SEQ ID NO:
- 14) and an optional linker in between, wherein the fusion protein binds to the human Her2/neu receptor.
2-64. (canceled)
Dependencies are inferred from the claim text.